HTG Molecular Diagnostics, Inc.

Equities

HTGMQ

US40434H3021

Advanced Medical Equipment & Technology

Market Closed - OTC Markets Other stock markets 12:27:20 2024-07-10 EDT			5-day change	1st Jan Change
0.0015 ^USD	0.00%		0.00%	+15.38%

2023	Motion for De Minimus Asset Sale Approved for HTG Molecular Diagnostics, Inc.	CI
2023	Motion for De Minimus Asset Sale Filed by HTG Molecular Diagnostics, Inc.	CI

HTG Molecular Diagnostics, Inc. Announces Preliminary Revenue Guidance for the Full Year of 2018

January 07, 2019 at 08:00 am

HTG Molecular Diagnostics, Inc. announced preliminary revenue guidance for the full year of 2018. For the period, the company reported total revenue for the full year 2018 is expected to be approximately $21.5 million, an increase of 46% over total revenue for the full year 2017.

Latest news about HTG Molecular Diagnostics, Inc.

Motion for De Minimus Asset Sale Approved for HTG Molecular Diagnostics, Inc.	23-08-25	CI
Motion for De Minimus Asset Sale Filed by HTG Molecular Diagnostics, Inc.	23-08-16	CI
Trustee/Examiner Appointed Under Chapter 11 for HTG Molecular Diagnostics, Inc.	23-07-21	CI
HTG Molecular Diagnostics, Inc.(OTCPK:HTGM.Q) dropped from NASDAQ Composite Index	23-06-14	CI
HTG Molecular Diagnostics, Inc.(NasdaqCM:HTGM) dropped from S&P TMI Index	23-06-08	CI
Htg Molecular Diagnostics, Inc. Announces Termination of Employment of Byron T. Lawson as Senior Vice President and Chief Commercial Officer	23-06-05	CI
HTG Molecular Diagnostics, Inc. Filed for Bankruptcy	23-06-05	CI
HTG Molecular Diagnostics, Inc. to Highlight the Advantages of its Drug Discovery Engine at the 2023 Biotechnology Innovation Organization	23-05-18	CI
Top Premarket Gainers	23-05-17	MT
HTG Molecular Diagnostics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10	CI
HC Wainwright Adjusts Price Target on HTG Molecular Diagnostics to $6 From $15, Maintains Buy Rating	23-04-03	MT
HTG Molecular Diagnostics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-30	CI
HTG Molecular Diagnostics, Inc. Auditor Raises 'Going Concern' Doubt	23-03-29	CI
Certain Warrants of HTG Molecular Diagnostics, Inc. are subject to a Lock-Up Agreement Ending on 22-FEB-2023.	23-02-21	CI
Certain Restricted Stock Units of HTG Molecular Diagnostics, Inc. are subject to a Lock-Up Agreement Ending on 22-FEB-2023.	23-02-21	CI
Certain Stock Options of HTG Molecular Diagnostics, Inc. are subject to a Lock-Up Agreement Ending on 22-FEB-2023.	23-02-21	CI
Certain Common Stock of HTG Molecular Diagnostics, Inc. are subject to a Lock-Up Agreement Ending on 22-FEB-2023.	23-02-21	CI
HTG Molecular Diagnostics, Inc. Provides a Year-End Update on its Drug Discovery Business and Attends LifeSci Partners 2023 Corporate Access Event	23-01-09	CI
HTG Molecular Diagnostics, Inc. Provides Revenue Guidance for Full Year 2022	23-01-06	CI
China's Move to End COVID Quarantine for Inbound Travelers Sparks Premarket Gains for US Equities	22-12-27	MT
Top Premarket Gainers	22-12-27	MT
HTG Molecular Diagnostics to Begin Trading on Split-Adjusted Basis on Wednesday	22-12-20	MT
Transcript : HTG Molecular Diagnostics, Inc. - Special Call	22-12-13
Wall Street Set to Open Higher as Investors Await Inflation Data, Fed Rate Decision in Coming Days	22-12-12	MT
US Futures Move Modestly Higher Monday Ahead of Inflation Data Tuesday, Fed Rate Decision Meeting Conclusion Wednesday	22-12-12	MT

Chart HTG Molecular Diagnostics, Inc.

Duration

Period

More charts

Company Profile

HTG Molecular Diagnostics, Inc. is a life science company. The Company is focused on advancing precision medicine and drug discovery through its transcriptome-wide profiling and advanced drug discovery platform technologies. The Company is engaged in the sales of its HTG EdgeSeq system and integrated next-generation sequencing-based (NGS-based) HTG EdgeSeq research use only (RUO) assays and from sample processing services. Its HTG EdgeSeq profiling technology measures ribonucleic acid (RNA) using deoxyribonucleic acid (DNA) nuclease protection probes (DNA protection probes). Its profiling product and service solutions enable targeted RNA profiling using a small amount of biological sample, in liquid or solid forms. Its menu of HTG EdgeSeq assays includes the HTG Transcriptome Panel (HTP), which is designed to measure approximately 20,000 mRNA targets using its HTG EdgeSeq technology, is automated on its HTG EdgeSeq system.

Sector

Advanced Medical Equipment & Technology

Calendar

2025-05-07 - Q1 2025 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
HTG MOLECULAR DIAGNOSTICS, INC.	+15.38%	3.32K
SARTORIUS AG	-27.76%	16.3B
INNER MONGOLIA FURUI MEDICAL SCIENCE CO., LTD.	+13.44%	1.79B
SHANGHAI MICROPORT EP MEDTECH CO., LTD.	-15.91%	1.4B
BIOTAGE AB	+40.76%	1.38B
REVENIO GROUP OYJ	+5.89%	833M
SHANGHAI AOHUA PHOTOELECTRICITY ENDOSCOPE CO., LTD.	-30.52%	799M
CONTEC MEDICAL SYSTEMS CO.,LTD	-38.05%	707M
CELLAVISION AB	+29.01%	606M
VAREX IMAGING CORPORATION	-26.54%	615M

Medical Diagnostic & Testing Equipment